Search Within

Matthew J Matasar

Formats
  1. Meeting Abstract (192)
  2. Journal Article (86)
  3. Book Section (4)
  4. Review (3)
  5. Correspondence (2)
  6. Editorial (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Survivorship Research (293)
  6. Population Sciences Research Program (113)

More Groups

People
  1. Andrew Zelenetz (118)
  2. David Straus (104)
  3. Ariela Noy (101)
  4. Paul Hamlin (100)
  5. Steven Horwitz (98)
  6. Alison Moskowitz (96)

More People

Years
  1. 2024 (9)
  2. 2023 (12)
  3. 2022 (43)
  4. 2021 (43)
  5. 2020 (23)
  6. 2019 (34)

More Years

Publications
  1. Blood (110)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (22)
  4. Biology of Blood and Marrow Transplantation (11)
  5. Clinical Lymphoma, Myeloma and Leukemia (11)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (120)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (29)
  4. Wiley Blackwell (26)
  5. Oxford University Press (13)
  6. John Wiley & Sons (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An individualized risk mitigation approach for safety: Experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk
    Meeting Abstract

    Diefenbach, C.; Assouline, S.; Bosch, F.; Cheah, C. Y.; Kim, W. S.; Matasar, M. J.; Panizo, C.; Yoon, D. H.; Bender, B.; Hernandez, G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Meeting Abstract

    Glaß, B.; Sehn, L. H.; Herrera, A. F.; Matasar, M.; Kamdar, M.; Assouline, S.; Hertzberg, M.; Kim, T. M.; Kim, W. S.; McMillan, A.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Follicular lymphoma: Recent and emerging therapies, treatment strategies, and remaining unmet needs
    Review

    Matasar, M. J.; Luminari, S.; Barr, P. M.; Barta, S. K.; Danilov, A. V.; Hill, B. T.; Phillips, T. J.; Jerkeman, M.; Magagnoli, M.; Nastoupil, L. J.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Prediagnosis cardiovascular risk and subsequent myocardial infarction (Ml) among lymphoma survivors
    Meeting Abstract

    Salz, T.; Zabor, E. C.; de Nully Brown, P.; Dalton, S. O.; Raghunathan, N. J.; Matasar, M. J.; Steingart, R.; Hjalgrim, H.; Specht, L.; Oeffinger, K. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Real-world assessment of practice efficiency with the introduction of subcutaneous rituximab
    Meeting Abstract

    Qiu, A.; Shapouri, S.; Drill, E. N.; Schade, J.; Ravelo, A.; Ni, A.; To, T. M.; Dawson, K. L.; Matasar, M. J.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Assouline, S. E.; Bosch, F.; Diefenbach, C. S. M.; Flinn, I.; Hong, J.; Kim, W. S.; Matasar, M. J.; Nastoupil, L. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Cost of disease progression in patients with metastatic breast, lung, and colorectal cancer
    Journal Article

    Reyes, C.; Engel-Nitz, N. M.; DaCosta Byfield, S.; Ravelo, A.; Ogale, S.; Bancroft, T.; Anderson, A.; Chen, M.; Matasar, M.
    The Oncologist (2019)

    Fulltext@MSK | Save